Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology

Biochemical Pharmacology

Volumn 91, Issue 2, 2014, Pages 135-143

  Rosfjord, Edward ^a,b   Lucas, Judy ^a,b   Li, Gang ^a,b,c   Gerber, Hans Peter ^a,b  

^a Oncology Research   (United States)

^b Pfizer Worldwide Research and Development   (United States)

^c Ignyta   (United States)

Author keywords

Biomarker development; Cancer drug development; Cancer stem cells; Preclinical oncology pharmacology models; Target identification and validation

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BREQUINAR; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; IROFULVEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; SAGOPILONE; TOPOTECAN; BIOLOGICAL MARKER;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; COLORECTAL CANCER; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MESENCHYME CELL; NEUROBLASTOMA; NONHUMAN; ONCOLOGY; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; RHABDOMYOSARCOMA; STROMA CELL; TUMOR XENOGRAFT; CANCER GROWTH; CANCER MODEL; CANCER PATIENT; CANCER RESEARCH; DRUG RESEARCH; DRUG SCREENING; ENGRAFTMENT; MOLECULAR PATHOLOGY; NEOPLASM; OUTCOME ASSESSMENT; PATIENT DERIVED TUMOR XENOGRAFT; PREDICTIVE VALUE; REVIEW; STROMA;

BIOMARKER DEVELOPMENT; CANCER DRUG DEVELOPMENT; CANCER STEM CELLS; PRECLINICAL ONCOLOGY PHARMACOLOGY MODELS; TARGET IDENTIFICATION AND VALIDATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HETEROGRAFTS; HUMANS; NEOPLASMS, EXPERIMENTAL;

EID: 84906790811     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.06.008     Document Type: Note

References (113)

1. J.A. DiMasi, J.M. Reichert, L. Feldman, and A. Malins Clinical approval success rates for investigational cancer drugs Clin Pharmacol Ther 94 2013 329 335
2. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3 2004 711 715 (Pubitemid 39173511)
3. S. Kopetz, R. Lemos, and G. Powis The promise of patient-derived xenografts: the best laid plans of mice and men Clin Cancer Res: Off J Am Assoc Cancer Res 18 2012 5160 5162
4. B.A. Ruggeri, F. Camp, and S. Miknyoczki Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery Biochem Pharmacol 87 2014 150 161
5. L.M. Cobb The behaviour of carcinoma of the large bowel in man following transplantation into immune deprived mice Br J Cancer 28 1973 400 411
6. H.H. Fiebig, C. Schuchhardt, H. Henss, L. Fiedler, and G.W. Lohr Comparison of tumor response in nude mice and in the patients Behring Institute Mitteilungen 74 1984 343 352
7. J.A. Houghton, and D.M. Taylor Maintenance of biological and biochemical characteristics of human colorectal tumours during serial passage in immune-deprived mice Br J Cancer 37 1978 199 212 (Pubitemid 8281319)
8. R.G. Pickard, L.M. Cobb, and G.G. Steel The growth kinetics of xenografts of human colorectal tumours in immune deprived mice Br J Cancer 31 1975 36 45
9. J.J. Tentler, A.C. Tan, C.D. Weekes, A. Jimeno, S. Leong, and T.M. Pitts et al. Patient-derived tumour xenografts as models for oncology drug development Nat Rev Clin Oncol 9 2012 338 350
10. F. Reyal, C. Guyader, C. Decraene, C. Lucchesi, N. Auger, and F. Assayag et al. Molecular profiling of patient-derived breast cancer xenografts Breast Cancer Res 14 2012 R11
11. Y.S. DeRose, G. Wang, Y.C. Lin, P.S. Bernard, S.S. Buys, and M.T. Ebbert et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes Nat Med 17 2011 1514 1520
12. P. Loukopoulos, K. Kanetaka, M. Takamura, T. Shibata, M. Sakamoto, and S. Hirohashi Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity Pancreas 29 2004 193 203 (Pubitemid 39304976)
13. X. Zhao, Z. Liu, L. Yu, Y. Zhang, P. Baxter, and H. Voicu et al. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma Neurooncol 14 2012 574 583
14. J. McEvoy, A. Ulyanov, R. Brennan, G. Wu, S. Pounds, and J. Zhang et al. Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma PloS ONE 7 2012 e42739
15. C.L. Morton, and P.J. Houghton Establishment of human tumor xenografts in immunodeficient mice Nat Protoc 2 2007 247 250 (Pubitemid 47040037)
16. L. Ding, B.J. Raphael, F. Chen, and M.C. Wendl Advances for studying clonal evolution in cancer Cancer Lett 340 2013 212 219
17. M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, and E. Gronroos et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing New Engl J Med 366 2012 883 892
18. G.G. Steel, and M.J. Peckham Human tumour xenografts: a critical appraisal Br J Cancer Suppl 4 1980 133 141 (Pubitemid 10047960)
19. A. Bertotti, G. Migliardi, F. Galimi, F. Sassi, D. Torti, and C. Isella et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer Cancer Discov 1 2011 508 523
20. S. Julien, A. Merino-Trigo, L. Lacroix, M. Pocard, D. Goere, and P. Mariani et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer Clin Cancer Res: Off J Am Assoc Cancer Res 18 2012 5314 5328
21. L.A. Petrillo, D.M. Wolf, A.M. Kapoun, N.J. Wang, A. Barczak, and Y. Xiao et al. Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors Breast Cancer Res Treat 135 2012 913 922
22. D. Siolas, and G.J. Hannon Patient-derived tumor xenografts: transforming clinical samples into mouse models Cancer Res 73 2013 5315 5319
23. M. Mattie, A. Christensen, M.S. Chang, W. Yeh, S. Said, and Y. Shostak et al. Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics Neoplasia 15 2013 1138 1150
24. C. Greenman, P. Stephens, R. Smith, G.L. Dalgliesh, C. Hunter, and G. Bignell et al. Patterns of somatic mutation in human cancer genomes Nature 446 2007 153 158 (Pubitemid 46398669)
25. M.R. Stratton, P.J. Campbell, and P.A. Futreal The cancer genome Nature 458 2009 719 724
26. L. Chin, J.N. Andersen, and P.A. Futreal Cancer genomics: from discovery science to personalized medicine Nat Med 17 2011 297 303
27. D.M. Berman, M.W. Bosenberg, R.L. Orwant, B.L. Thurberg, G.F. Draetta, and C.D. Fletcher et al. Investigative pathology: leading the post-genomic revolution Lab Invest: J Tech Methods Pathol 92 2012 4 8
28. M. Nunes, L.B. Weiswald, P. Vrignaud, S. Vacher, E. Turlotte, and S. Richon et al. P05.08 similar PI3K and RTK-RAS status in patient derived colorectal cancer-xenografts and patients Ann Oncol 24 2013 i31
29. P. Smith, D. Sutton, A. Bertotti, L. Trusolino, S. Airhart, and M.S. Tsao et al. Translational Proof-of-Concept (TransPoC), a not-for-profit research organization enabling access to large-scale translational oncology platforms: the Patient-Derived Xenograft network Proceedings of the 105th annual meeting of the American Association for Cancer Research 5-9 April 2014 2014 AACR San Diego, CA, Philadelphia (PA) (Abstract 1191)
30. E. Vinolo, E. Marangoni, V. Serra, F. Amant, A. Bertotti, and A.V. Biankin et al. Abstract A8: the EurOPDX consortium: sharing patient tumor-derived xenografts for collaborative multicentric preclinical trials Mol Cancer Ther 12 2013 A8
31. V.C. Daniel, L. Marchionni, J.S. Hierman, J.T. Rhodes, W.L. Devereux, and C.M. Rudin et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro Cancer Res 69 2009 3364 3373
32. R.E. Sobel, and M.D. Sadar Cell lines used in prostate cancer research: a compendium of old and new lines - part 2 J Urol 173 2005 360 372
33. R.E. Sobel, and M.D. Sadar Cell lines used in prostate cancer research: a compendium of old and new lines - part 1 J Urol 173 2005 342 359
34. N.T. Ihle, G. Powis, and S. Kopetz PI-3-kinase inhibitors in colorectal cancer Curr Cancer Drug Targ 11 2011 190 198
35. B.C. Giovanella, D.M. Vardeman, L.J. Williams, D.J. Taylor, P.D. de Ipolyi, and P.J. Greeff et al. Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene Journal international du cancer Int J Cancer 47 1991 66 71
36. J. Mattern, M. Bak, E.W. Hahn, and M. Volm Human tumor xenografts as model for drug testing Cancer Metastasis Rev 7 1988 263 284
37. P. Beckhove, F. Schutz, I.J. Diel, E.F. Solomayer, G. Bastert, and J. Foerster et al. Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice Journal international du cancer Int J Cancer 105 2003 444 453 (Pubitemid 36578546)
38. P. Cottu, E. Marangoni, F. Assayag, P. de Cremoux, A. Vincent-Salomon, and C. Guyader et al. Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts Breast Cancer Res Treat 133 2012 595 606
39. E. Marangoni, A. Vincent-Salomon, N. Auger, A. Degeorges, F. Assayag, and P. de Cremoux et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays Clin Cancer Res: Off J Am Assoc Cancer Res 13 2007 3989 3998 (Pubitemid 47037607)
40. L.D. Shultz, B.L. Lyons, L.M. Burzenski, B. Gott, X. Chen, and S. Chaleff et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells J Immunol 174 2005 6477 6489 (Pubitemid 40663843)
41. L. de Plater, A. Lauge, C. Guyader, M.F. Poupon, F. Assayag, and P. de Cremoux et al. Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation Br J Cancer 103 2010 1192 1200
42. M. Moro, G. Bertolini, M. Tortoreto, U. Pastorino, G. Sozzi, and L. Roz Patient-derived xenografts of non-small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells J Biomed Biotechnol 2012 2012 568567
43. S. Peng, C.J. Creighton, Y. Zhang, B. Sen, T. Mazumdar, and J.N. Myers et al. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers J Transl Med 11 2013 198
44. M.R. Simpson-Abelson, G.F. Sonnenberg, H. Takita, S.J. Yokota, T.F. Conway Jr., and R.J. Kelleher Jr. et al. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice J Immunol 180 2008 7009 7018
45. K.P. Olive, M.A. Jacobetz, C.J. Davidson, A. Gopinathan, D. McIntyre, and D. Honess et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Science 324 2009 1457 1461
46. D.D. Von Hoff, R.K. Ramanathan, M.J. Borad, D.A. Laheru, L.S. Smith, and T.E. Wood et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial J Clin Oncol: Off J Am Soc Clin Oncol 29 2011 4548 4554
47. D.D. Von Hoff, T. Ervin, F.P. Arena, E.G. Chiorean, J. Infante, and M. Moore et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine New Engl J Med 369 2013 1691 1703
48. D. Bonnet, and J.E. Dick Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell Nat Med 3 1997 730 737 (Pubitemid 27298715)
49. T. Reya, S.J. Morrison, M.F. Clarke, and I.L. Weissman Stem cells, cancer, and cancer stem cells Nature 414 2001 105 111 (Pubitemid 33041634)
50. S.K. Singh, C. Hawkins, I.D. Clarke, J.A. Squire, J. Bayani, and T. Hide et al. Identification of human brain tumour initiating cells Nature 432 2004 396 401 (Pubitemid 39551674)
51. P. Dalerba, S.J. Dylla, I.K. Park, R. Liu, X. Wang, and R.W. Cho et al. Phenotypic characterization of human colorectal cancer stem cells Proc Natl Acad Sci U S A 104 2007 10158 10163 (Pubitemid 47175279)
52. C.A. O'Brien, A. Pollett, S. Gallinger, and J.E. Dick A human colon cancer cell capable of initiating tumour growth in immunodeficient mice Nature 445 2007 106 110 (Pubitemid 46067310)
53. L. Ricci-Vitiani, D.G. Lombardi, E. Pilozzi, M. Biffoni, M. Todaro, and C. Peschle et al. Identification and expansion of human colon-cancer-initiating cells Nature 445 2007 111 115 (Pubitemid 46067311)
54. P.C. Hermann, S.L. Huber, T. Herrler, A. Aicher, J.W. Ellwart, and M. Guba et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer Cell Stem Cell 1 2007 313 323 (Pubitemid 47355323)
55. J.E. Visvader, and G.J. Lindeman Cancer stem cells in solid tumours: accumulating evidence and unresolved questions Nat Rev Cancer 8 2008 755 768
56. L.V. Nguyen, R. Vanner, P. Dirks, and C.J. Eaves Cancer stem cells: an evolving concept Nat Rev Cancer 12 2012 133 143
57. J.M. Rosen, and C.T. Jordan The increasing complexity of the cancer stem cell paradigm Science 324 2009 1670 1673
58. X. Li, M.T. Lewis, J. Huang, C. Gutierrez, C.K. Osborne, and M.F. Wu et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy J Natl Cancer Instit 100 2008 672 679
59. M.F. Clarke, J.E. Dick, P.B. Dirks, C.J. Eaves, C.H. Jamieson, and D.L. Jones et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells Cancer Res 66 2006 9339 9344 (Pubitemid 44623625)
60. C.A. O'Brien, A. Kreso, and C.H. Jamieson Cancer stem cells and self-renewal Clin Cancer Res: Off J Am Assoc Cancer Res 16 2010 3113 3120
61. P. Valent, D. Bonnet, R. De Maria, T. Lapidot, M. Copland, and J.V. Melo et al. Cancer stem cell definitions and terminology: the devil is in the details Nat Rev Cancer 12 2012 767 775
62. C.A. Huff, W.H. Matsui, B.D. Smith, and R.J. Jones Strategies to eliminate cancer stem cells: clinical implications Eur J Cancer 42 2006 1293 1297 (Pubitemid 44208864)
63. G. Bertolini, L. Roz, P. Perego, M. Tortoreto, E. Fontanella, and L. Gatti et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment Proc Natl Acad Sci U S A 106 2009 16281 16286
64. T. Schatton, G.F. Murphy, N.Y. Frank, K. Yamaura, A.M. Waaga-Gasser, and M. Gasser et al. Identification of cells initiating human melanomas Nature 451 2008 345 349
65. T. Schatton, U. Schutte, N.Y. Frank, Q. Zhan, A. Hoerning, and S.C. Robles et al. Modulation of T-cell activation by malignant melanoma initiating cells Cancer research. 70 2010 697 708
66. P. Sapra, M. Damelin, J. Dijoseph, K. Marquette, K.G. Geles, and J. Golas et al. Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells Mol Cancer Ther 12 2013 38 47
67. E. Boven, B. Winograd, D.P. Berger, M.P. Dumont, B.J. Braakhuis, and O. Fodstad et al. preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study Cancer Res 52 1992 5940 5947
68. T. Voskoglou-Nomikos, J.L. Pater, and L. Seymour Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models Clin Cancer Res: Off J Am Assoc Cancer Res 9 2003 4227 4239 (Pubitemid 37204044)
69. R. Krumbach, J. Schuler, M. Hofmann, T. Giesemann, H.H. Fiebig, and T. Beckers Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance Eur J Cancer 47 2011 1231 1243
70. L.A. Diaz Jr., R.T. Williams, J. Wu, I. Kinde, J.R. Hecht, and J. Berlin et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers Nature 486 2012 537 540
71. S.P. Shah, A. Roth, R. Goya, A. Oloumi, G. Ha, and Y. Zhao et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers Nature 486 2012 395 399
72. E.E. Embuscado, D. Laheru, F. Ricci, K.J. Yun, S. de Boom Witzel, and A. Seigel et al. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy Cancer Biol Ther 4 2005 548 554 (Pubitemid 41351229)
73. M.A. Rubin, M. Putzi, N. Mucci, D.C. Smith, K. Wojno, and S. Korenchuk et al. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer Clin Cancer Res: Off J Am Assoc Cancer Res 6 2000 1038 1045 (Pubitemid 30159365)
74. H.H. Fiebig, V. Vuaroqueaux, A. Korrat, F. Foucault, and T. Beckers Predictive gene signatures for bevacizumab and cetuximab as well as cytotoxic agents Int J Clin Pharmacol Ther 50 2012 70 71
75. H.H. Fiebig, W.A. Dengler, and T. Roth Human tumor xenografts: predictivity, characterization and discovery of new anticancer agents H.H. Fiebig, A.M. Burger, Relevance of tumor models for anticancer drug development 1999 Karger Basel 29 50
76. D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, and A. Santoro et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer New Engl J Med 351 2004 337 345 (Pubitemid 38944402)
77. F. Nemati, C. Daniel, F. Arvelo, M.E. Legrier, B. Froget, and A. Livartowski et al. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts Anti-cancer Drugs 21 2010 25 32
78. A. Ardizzoni, H. Hansen, P. Dombernowsky, T. Gamucci, S. Kaplan, and P. Postmus et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group J Clin Oncol: Off J Am Soc Clin Oncol 15 1997 2090 2096
79. M. Hidalgo, E. Bruckheimer, N.V. Rajeshkumar, I. Garrido-Laguna, E. De Oliveira, and B. Rubio-Viqueira et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer Mol Cancer Ther 10 2011 1311 1316
80. M. Leggas, C.F. Stewart, M.H. Woo, M. Fouladi, P.J. Cheshire, and J.K. Peterson et al. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts Clin Cancer Res: Off J Am Assoc Cancer Res 8 2002 3000 3007 (Pubitemid 35025750)
81. S.G. Eckhardt, S.D. Baker, C.D. Britten, M. Hidalgo, L. Siu, and L.A. Hammond et al. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies J Clin Oncol: Off J Am Soc Clin Oncol 18 2000 4086 4097 (Pubitemid 32038401)
82. J.K. Peterson, and P.J. Houghton Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development Eur J Cancer 40 2004 837 844 (Pubitemid 38519762)
83. R.J. Schilder, J.A. Blessing, M.S. Shahin, D.S. Miller, K.S. Tewari, and C.Y. Muller et al. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial Int J Gynecol Cancer: Off J Int Gynecol Cancer Soc 20 2010 1137 1141
84. J. Maroun, J. Ruckdeschel, R. Natale, R. Morgan, B. Dallaire, and R. Sisk et al. Multicenter phase II study of brequinar sodium in patients with advanced lung cancer Cancer Chemother Pharmacol 32 1993 64 66 (Pubitemid 23105009)
85. X. Dong, J. Guan, J.C. English, J. Flint, J. Yee, and K. Evans et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy Clin Cancer Res: Off J Am Assoc Cancer Res 16 2010 1442 1451
86. S. Hammer, A. Sommer, I. Fichtner, M. Becker, J. Rolff, and J. Merk et al. Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer Clin Cancer Res: Off J Am Assoc Cancer Res 16 2010 1452 1465
87. D.F. Heigener, J. von Pawel, C. Eschbach, A. Brune, A. Schmittel, and T. Schmelter et al. Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer Lung Cancer 80 2013 319 325
88. H. Wong, E.F. Choo, B. Alicke, X. Ding, H. La, and E. McNamara et al. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response Clin Cancer Res: Off J Am Assoc Cancer Res 18 2012 3846 3855
89. M. Das Thakur, F. Salangsang, A.S. Landman, W.R. Sellers, N.K. Pryer, and M.P. Levesque et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance Nature 494 2013 251 255
90. C.S. Karapetis, S. Khambata-Ford, D.J. Jonker, C.J. O'Callaghan, D. Tu, and N.C. Tebbutt et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer New Engl J Med 359 2008 1757 1765
91. A. Lievre, J.B. Bachet, V. Boige, A. Cayre, D. Le Corre, and E. Buc et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol: Off J Am Soc Clin Oncol 26 2008 374 379 (Pubitemid 351171687)
92. S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer J Natl Cancer Inst 101 2009 1308 1324
93. J. Tol, and C.J. Punt Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review Clin Ther 32 2010 437 453
94. R.G. Amado, M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, and D.J. Freeman et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol: Off J Am Soc Clin Oncol 26 2008 1626 1634
95. M.L. Rothenberg Efficacy and toxicity of irinotecan in patients with colorectal cancer Semin Oncol 25 1998 39 46 (Pubitemid 28478054)
96. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70 (Pubitemid 30046295)
97. U. Kortmann, J.N. McAlpine, H. Xue, J. Guan, G. Ha, and S. Tully et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts Clin Cancer Res: Off J Am Assoc Cancer Res 17 2011 783 791
98. C.L. Scott, M.A. Becker, P. Haluska, and G. Samimi Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment Front Oncol 3 2013 295
99. M.W. Audeh, J. Carmichael, R.T. Penson, M. Friedlander, B. Powell, and K.M. Bell-McGuinn et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 376 2010 245 251
100. K.A. Gelmon, M. Tischkowitz, H. Mackay, K. Swenerton, A. Robidoux, and K. Tonkin et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study Lancet Oncol 12 2011 852 861
101. B.A. Teicher Tumor models for preclinical development of targeted agents Fortschritte der Arzneimittelforschung, Progres des recherches pharmaceutiques Progress Drug Res. 63 2005 43 66 (Pubitemid 41406429)
102. H.P. Gerber, and N. Ferrara Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies Cancer Res 65 2005 671 680 (Pubitemid 40216420)
103. G. Bergers, K. Javaherian, K.M. Lo, J. Folkman, and D. Hanahan Effects of angiogenesis inhibitors on multistage carcinogenesis in mice Science 284 1999 808 812 (Pubitemid 29291347)
104. I. Fichtner, J. Rolff, R. Soong, J. Hoffmann, S. Hammer, and A. Sommer et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers Clin Cancer Res: Off J Am Assoc Cancer Res 14 2008 6456 6468
105. S.G. Arbuck Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer Cancer 63 1989 1036 1044 (Pubitemid 19081270)
106. P.J. Houghton, and J.A. Houghton Evaluation of single-agent therapy in human colorectal tumour xenografts Br J Cancer 37 1978 833 840 (Pubitemid 8344905)
107. B.J. Cedermark, M.S. Didolkar, and E.G. Elias Methyl-CCNU (NSC-95441) in advanced colorectal carcinoma after failure of 5-fluorouracil (NSC-19893) therapy Cancer Treat Rep 60 1976 235 238
108. R. Chapman, L. Itri, R. Gralla, D. Kelsen, E. Casper, and R. Golbey Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC) Cancer Chemother Pharmacol 7 1982 205 207 (Pubitemid 12157022)
109. L.M. Itri, R.J. Gralla, R.A. Chapman, D.P. Kelsen, E.S. Casper, and R.B. Golbey Phase II trial of VP-16-213 in non-small-cell lung cancer Am J Clin Oncol 5 1982 45 47 (Pubitemid 12075240)
110. U. Gatzemeier, M. Heckmayr, R. Neuhauss, D. Hossfeld, W. Achterrath, and L. Lenaz Phase II studies with carboplatin in non-small cell lung cancer Semin Oncol 17 1990 25 31 (Pubitemid 20060003)
111. H.H. Hansen, and J.B. Sorensen Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: a review Semin Oncol 24 1997 S7-38-S7-41
112. U. Gatzemeier, M. Heckmayr, R. Neuhauss, I. Schluter, J.V. Pawel, and H. Wagner et al. Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer Lung Cancer 12 Suppl. 2 1995 S101 S106
113. F. Fossella, J.R. Pereira, J. von Pawel, A. Pluzanska, V. Gorbounova, and E. Kaukel et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group J Clin Oncol: Off J Am Soc Clin Oncol 21 2003 3016 3024 (Pubitemid 46606280)